52 Week Range
As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
CanSino Says Co's COVID-19 Vaccine Approved For Emergency Use In Chile
CanSino Biologics FY Loss & Total Comprehensive Loss RMB396.6 Mln
CanSino Biologics Says NMPA Approved Clinical Trial Application For COVID-19 Vaccine For Inhalation
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
Biotechnology & Drugs
Executive Chairman of the Board, Chief Executive Officer, General Manager
Chief Financial Officer, Secretary of the Board
Shou Bai Chao
Chief Operating Officer, Deputy General Manager, Executive Director
Senior Vice President, Deputy General Manager, Executive Director
Senior Vice President, Deputy General Manager
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The physician heading a Phase III clinical trial in Pakistan for a Chinese COVID-19 vaccine candidate has urged people to volunteer for the trial, overcoming the resistance in the country to immunisation programmes.
Pakistan has launched Phase III clinical trials for CanSino Biologics' COVID-19 vaccine candidate, a government minister and an official at the Chinese pharmaceutical company said on Tuesday.
Pakistan has launched Phase III clinical trials for Chinese company Cansinobio's COVID-19 vaccine candidate, a government minister and an official at the pharmaceutical company said on Tuesday.
Researchers plan to start a clinical trial for an additional dose of a coronavirus vaccine candidate co-developed by China's CanSino Biologics Inc and a military-backed research unit, clinical trial registry data showed.
Falling COVID-19 infection numbers in Pakistan will not affect a Phase 3 clinical trial for a potential vaccine being developed by China's CanSino Biologics, which is expected to begin this month, according to officials running the trial.
China's CanSino Biologics Inc said on Wednesday that expert opinion on its high-profile coronavirus vaccine candidate should not be followed "blindly" without sufficient clinical trial data.
China's CanSino Biologics Inc said on Wednesday expert opinion on its high-profile coronavirus vaccine candidate should not be followed "blindly" without sufficient clinical trial data.
China said on Thursday that the end to a partnership on a coronavirus vaccine between Chinese firm CanSino Biologics and Canada is unrelated to diplomatic relations between the countries.
Canada's National Research Council (NRC) said on Wednesday that it has ended its partnership for a coronavirus vaccine with CanSino Biologics, saying the Chinese company lacks the authority to ship the vaccine at this time.
Chinese vaccine-maker CanSino Biologics said on Tuesday domestic bureaucratic indecision was the reason behind the failure of a coronavirus vaccine partnership with Canada, the Globe and Mail reported, citing the company's chief executive officer.
Pakistan's drug regulator greenlit the country's first Phase 3 clinical trial for a potential COVID-19 vaccine, which is being developed by China's CanSino Biologics (CanSino) and Beijing Institute of Biotechnology.
China's CanSino Biologics said on Tuesday it had not started enrolling participants for a late-stage trial of its potential COVID-19 vaccine Ad5-nCoV.
Russia's Petrovax has started a late-stage trial of a COVID-19 candidate vaccine from CanSino Biologics Inc in the country, records show, as the Chinese drug firm steps up testing abroad to close in on regulatory approval.
A late-stage trial of a COVID-19 candidate vaccine from CanSino Biologics Inc has started in Russia, registration records showed, as the Chinese pharmaceutical firm steps up testing abroad to close in on regulatory approval.
China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.
Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China's CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday.
A vaccine against the coronavirus developed by CanSino Biologics Inc <6185.HK> and China's military research unit appears to be safe and induced immune responses in most subjects in a closely-watched mid-stage study, researchers said on Monday.
A COVID-19 vaccine developed by CanSino Biologics Inc and China's military research unit has shown to be safe and induced immune response in most of the recipients who got one shot, researchers said on Monday.
Chinese vaccine developer CanSino Biologics is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, its co-founder said on Saturday.
China's military has received the greenlight to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics <6185.HK> after clinical trials proved it was safe and showed some efficacy, the company said on Monday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.